Form 4: Revance Therapeutics CEO Mark Foley Acquires Shares Through Employee Stock Purchase Plan

Revance Therapeutics CEO Mark Foley acquired 1,000 shares of common stock through the company's Employee Stock Purchase Plan on June 30, 2024.

Summary

• On June 30, 2024, Mark Foley, CEO of Revance Therapeutics, acquired 1,000 shares of common stock through the company's Employee Stock Purchase Plan.
• The shares were purchased at a price of $2.1845 per share.
• Following the transaction, Mr. Foley directly owns 995,935 shares of Revance Therapeutics common stock.
• Additionally, 110,913 shares are held indirectly through the Foley Family Trust.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a routine transaction. The CEO purchasing shares can be seen as a slightly positive signal, but it's a small amount relative to their total holdings.

Positives

• The CEO's participation in the Employee Stock Purchase Plan could be viewed positively as it demonstrates confidence in the company's future.

Industry Context

This filing is a routine disclosure related to insider trading activity and doesn't necessarily reflect broader industry trends.

Stakeholder Impact

• The transaction has a minimal impact on stakeholders as it involves a small number of shares acquired through an employee stock purchase plan.

Key Dates

Keywords

Revance Therapeutics, Mark Foley, RVNC, Employee Stock Purchase Plan, Share Acquisition, Beneficial Ownership, Form 4, CEO